Last reviewed · How we verify
NCT03041987: C-STRIDE
Chinese Cohort Study of Chronic Kidney Disease
trial testing Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc in Renal Insufficiency, Chronic in 5,000 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | Peking University First Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 January 2012 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc
Conditions studied
- Renal Insufficiency, Chronic — all drugs for Renal Insufficiency, Chronic →
Sponsor
Peking University First Hospital
Who can join
Adults 18 to 74, any sex, with Renal Insufficiency, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to explore underlying mechanisms of chronic kidney disease progression and its association with adverse consequences. It will enroll approximately 5000 pre-dialysis chronic kidney disease patients aged between 18 and 74 years in mainland China and follow-up for at least 5 years. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at baseline and annually. The principal clinical outcomes of the study consist of renal disease events, cardiovascular events, and death.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE).
Yuan Q, Wang J, Peng Z, Zhou Q, et al · · 2019 · cited 80× · PMID 30876475 · DOI 10.1186/s12967-019-1808-4 -
Urinary magnesium predicts risk of cardiovascular disease in Chronic Kidney Disease stage 1-4 patients.
Yuan Q, Xie Y, Peng Z, Wang J, et al · · 2021 · cited 7× · PMID 33160701 · DOI 10.1016/j.clnu.2020.10.036
Verify or expand the search:
- PubMed search for NCT03041987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Insufficiency, Chronic
Currently open trials in the same condition.
- NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
- NCT07447375 — Exercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality · NA · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07292311 — Reliability of Muscle Strength and Activation Assessment Tools and Effects of an Online Therapeutic Exercise Program in · NA · active not recruiting
- NCT06863194 — Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial · Phase 1, PHASE2 · recruiting
Other Peking University First Hospital trials
Trials by the same sponsor.
- NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
- NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
- NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
- NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
- NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03041987 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03041987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing